BioStock: Egetis strengthens regulatory path for Emcitate following positive ReTRIACt data
Egetis Therapeutics presents an eventful third quarter. The most central news of the quarter is the positive results from the ReTRIACt study, which now forms an important part of the company's upcoming NDA application in the US. Egetis plans to initiate a rolling submission in December. BioStock contacted CEO Nicklas Westerholm to find out more.
See the interview biostock.se:
Egetis strengthens regulatory path for Emcitate following positive ReTRIACt data
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/